Which antibiotic is Actinomycosis sensitive to?
Which of the following is a synthetic estrogen?
What is the primary cardiotoxic effect of bupivacaine?
Which of the following best describes a Type B adverse drug reaction?
Which of the following statements about dopamine is false?
Which of the following is a centrally acting antihypertensive drug?
Which of the following statements about Conivaptan is correct?
Which medication increases the efficacy of salmeterol when used together?
Desmopressin is preferred over vasopressin because it:
Which of the following has the least glucocorticoid activity?
NEET-PG 2012 - Pharmacology NEET-PG Practice Questions and MCQs
Question 51: Which antibiotic is Actinomycosis sensitive to?
- A. Streptomycin
- B. Nystatin
- C. Doxycycline
- D. Penicillin (Correct Answer)
Explanation: ***Penicillin*** - **Penicillin** is the **antibiotic of choice** for treating Actinomycosis due to the organism's high sensitivity. - Treatment typically involves a **long course** of high-dose penicillin for several months. *Streptomycin* - **Streptomycin** is an **aminoglycoside antibiotic** primarily used for **tuberculosis** and some gram-negative bacterial infections. - It is **not effective** against Actinomyces species. *Nystatin* - **Nystatin** is an **antifungal medication** used to treat **yeast infections**, particularly Candida. - It has **no antibacterial activity** and thus no role in treating Actinomycosis. *Doxycycline* - While **doxycycline** can be used as an **alternative** in patients allergic to penicillin, it is **not the primary choice**. - Its effectiveness is generally less pronounced than penicillin, and it's reserved for second-line treatment.
Question 52: Which of the following is a synthetic estrogen?
- A. Estrone
- B. Estriol
- C. Estradiol
- D. Diethylstilbestrol (Correct Answer)
Explanation: ***Diethylstilbestrol*** - **Diethylstilbestrol (DES)** is a **synthetic non-steroidal estrogen** that was historically used as a medication, particularly to prevent miscarriage. - Its use was discontinued after being linked to various adverse effects, including **vaginal clear cell adenocarcinoma** in female offspring whose mothers took DES during pregnancy. *Estrone* - **Estrone** is one of the three major **naturally occurring endogenous estrogens** in humans. - It is the primary estrogen during **menopause** and is derived from androstenedione. *Estriol* - **Estriol** is another of the three major **naturally occurring estrogens**, predominantly produced during **pregnancy** by the placenta. - It is often used as a marker for fetal well-being. *Estradiol* - **Estradiol** is the **most potent and abundant naturally occurring estrogen** in women during their reproductive years. - It plays a crucial role in the development and maintenance of female reproductive tissues and secondary sexual characteristics.
Question 53: What is the primary cardiotoxic effect of bupivacaine?
- A. Depressed pacemaker activity (Correct Answer)
- B. Toxic compound damaging myocardial cells
- C. Depressed neural control on heart
- D. Vascular thrombosis and Myocardial ischemia
Explanation: ***Depressed pacemaker activity*** - **Bupivacaine** is a potent **local anesthetic** that blocks voltage-gated **sodium channels** in myocardial cells with **high affinity** and **slow dissociation kinetics**. - This prolonged channel blockade leads to decreased cardiac excitability and **depressed automaticity** of pacemaker cells, particularly affecting the **SA node** and **His-Purkinje system**. - Results in slowing of the **heart rate**, **bradyarrhythmias**, **conduction blocks**, and potentially **ventricular arrhythmias** or **asystole**. - Bupivacaine is **more cardiotoxic** than other local anesthetics due to its **lipophilicity** and prolonged binding to cardiac sodium channels. *Toxic compound damaging myocardial cells* - While **bupivacaine** is cardiotoxic, its primary mechanism is not direct **cellular damage** through cytotoxic effects, oxidative stress, or cell membrane lysis. - The toxicity is predominantly due to **electrophysiological effects** on ion channels, interfering with normal cardiac conduction and contractility. *Depressed neural control on heart* - **Bupivacaine's** cardiotoxicity primarily affects the **myocardium directly** through sodium channel blockade, rather than indirectly through the **autonomic nervous system**. - Although high systemic concentrations can affect the **central nervous system** (causing seizures and CNS depression), the direct cardiac effects occur independently of neural influence. *Vascular thrombosis and Myocardial ischemia* - **Bupivacaine** cardiotoxicity does not typically involve formation of **thrombi** or mechanisms leading to **myocardial ischemia** through coronary artery occlusion. - Its effects are predominantly on the **electrical conduction system**, **myocardial contractility**, and **cardiac ion channels**, not the vascular supply to the heart.
Question 54: Which of the following best describes a Type B adverse drug reaction?
- A. Augmented effect of drug
- B. Effect seen on chronic use of drug
- C. Delayed effect of drug
- D. Unpredictable bizarre reaction (Correct Answer)
Explanation: ***Unpredictable bizarre reaction*** - Type B reactions are **unpredictable**, **bizarre**, and not directly related to the drug's known pharmacological actions. - They often involve **immunological reactions** or genetic predispositions, such as allergies or idiosyncratic responses. *Augmented effect of drug* - This describes a **Type A** adverse drug reaction, which is predictable and results from an **exaggerated pharmacological effect** of the drug. - It is typically dose-dependent and can be managed by adjusting the dosage. *Effect seen on chronic use of drug* - This description can apply to several types of adverse reactions, but it commonly relates to **Type C (chronic) reactions**, where effects occur only after prolonged exposure. - These reactions might be due to **cumulative toxicity** or adaptive changes in the body. *Delayed effect of drug* - This aligns with **Type D (delayed) adverse drug reactions**, which manifest long after the drug exposure has ended or after a period of latency. - Examples include **carcinogenesis** or teratogenesis, occurring months or years later.
Question 55: Which of the following statements about dopamine is false?
- A. Improves renal perfusion
- B. Causes Vasoconstriction
- C. Causes increase in GI Ischemia (Correct Answer)
- D. Positive ionotropic
Explanation: ***Causes increase in GI Ischemia*** (FALSE Statement) - This statement is **incorrect and misleading** as dopamine does not primarily "cause increase in GI ischemia" - While dopamine at **higher doses** can cause **splanchnic vasoconstriction** via alpha-1 receptors, this is not characterized as "causing GI ischemia" in standard pharmacology - GI ischemia is a potential adverse effect in susceptible patients, but not a primary pharmacological effect or standard clinical description of dopamine *Positive inotropic* (TRUE Statement) - Dopamine is a **catecholamine** with dose-dependent effects; at **moderate doses (5-10 mcg/kg/min)**, it stimulates **beta-1 adrenergic receptors** in the heart - This beta-1 stimulation leads to increased **myocardial contractility** and **heart rate**, thus exerting a **positive inotropic effect** - This is a well-established therapeutic effect of dopamine *Improves renal perfusion* (TRUE Statement) - At **low doses (0.5-3 mcg/kg/min)**, dopamine selectively activates **dopamine-1 (D1) receptors** in the renal vasculature - This activation causes **renal vasodilation**, leading to increased **renal blood flow**, improved **glomerular filtration rate**, and enhanced **sodium excretion** - This "renal dose" effect is a classic pharmacological property of dopamine *Causes Vasoconstriction* (TRUE Statement) - At **high doses (>10 mcg/kg/min)**, dopamine primarily stimulates **alpha-1 adrenergic receptors** - This leads to generalized **vasoconstriction**, increasing **systemic vascular resistance** and **blood pressure** - This dose-dependent alpha effect is well-documented
Question 56: Which of the following is a centrally acting antihypertensive drug?
- A. Phenoxybenzamine
- B. Propranolol
- C. Prazosin
- D. Methyldopa (Correct Answer)
Explanation: ***Methyldopa*** - **Methyldopa** is a **prodrug** that is converted to **alpha-methylnorepinephrine** in the brain, which then stimulates **alpha-2 adrenergic receptors** in the brainstem. - This stimulation reduces **sympathetic outflow** from the central nervous system, leading to decreased heart rate, stroke volume, and peripheral vascular resistance, thus lowering blood pressure. *Phenoxybenzamine* - **Phenoxybenzamine** is an **alpha-1 and alpha-2 adrenergic receptor antagonist** (non-selective alpha blocker) that primarily acts peripherally. - It causes **vasodilation** by blocking alpha-1 receptors on smooth muscle, which reduces peripheral vascular resistance. *Propranolol* - **Propranolol** is a **non-selective beta-blocker** that primarily acts on peripheral beta-adrenergic receptors. - It reduces heart rate and cardiac output by blocking **beta-1 receptors** in the heart and can also affect beta-2 receptors in the lungs and vasculature. *Prazosin* - **Prazosin** is a **selective alpha-1 adrenergic receptor antagonist** that acts primarily on peripheral blood vessels. - It causes **vasodilation** in both arteries and veins by blocking alpha-1 receptors, which reduces both preload and afterload, lowering blood pressure.
Question 57: Which of the following statements about Conivaptan is correct?
- A. It is a vasopressin antagonist. (Correct Answer)
- B. It selectively acts on V2 receptors.
- C. It is administered orally.
- D. All of the options.
Explanation: ***It is a vasopressin antagonist.*** * **Conivaptan** is a non-peptide, dual **vasopressin V1A and V2 receptor antagonist**, meaning it blocks the action of vasopressin. * By blocking vasopressin, it promotes **aquaresis** (excretion of solute-free water), which is beneficial in conditions like **hyponatremia**. * *It selectively acts on V2 receptors.* * **Conivaptan** is a **dual antagonist**, blocking both **V1A and V2 receptors**, not just V2. * **Tolvaptan**, in contrast, is a selective **V2 receptor antagonist**. * *It is administered orally.* * **Conivaptan** is typically administered intravenously, particularly in hospital settings for acute hyponatremia. * **Tolvaptan** is the orally administered vasopressin antagonist. * *All of the options.* * Since Conivaptan is not selectively acting on V2 receptors and is not administered orally, this option is incorrect.
Question 58: Which medication increases the efficacy of salmeterol when used together?
- A. Corticosteroid (Correct Answer)
- B. Theophylline
- C. Ipratropium
- D. Sodium cromoglycate
Explanation: ***Corticosteroid*** - **Corticosteroids** act synergistically with **beta-2 agonists** like salmeterol by increasing the number and sensitivity of beta-2 receptors on bronchial smooth muscle cells. - They also reduce inflammation, which contributes to airway hyperresponsiveness, thereby improving the overall efficacy of bronchodilators. *Theophylline* - **Theophylline** is a methylxanthine that causes bronchodilation through inhibition of phosphodiesterase, but it is not directly synergistic with **salmeterol** in potentiating its primary action. - While both treat airway obstruction, their mechanisms are distinct, and theophylline has a narrow therapeutic index with significant side effects. *Ipratropium* - **Ipratropium** is an **anticholinergic bronchodilator** that blocks muscarinic receptors, leading to bronchodilation. - Its mechanism of action is different from that of **salmeterol (a beta-2 agonist)**, and while they can be used together for additive bronchodilation, ipratropium does not directly increase the efficacy of salmeterol itself. *Sodium cromoglycate* - **Sodium cromoglycate** is a **mast cell stabilizer** that prevents the release of inflammatory mediators, primarily used for asthma prophylaxis. - It does not have direct bronchodilatory effects and does not enhance the bronchodilatory action of **salmeterol**.
Question 59: Desmopressin is preferred over vasopressin because it:
- A. Is more potent and has little vasoconstrictor activity (Correct Answer)
- B. Is more potent than vasopressin
- C. Has little vasoconstrictor activity
- D. Is more selective for V2 receptors than vasopressin
Explanation: **Is more potent and has little vasoconstrictor activity** - **Desmopressin** is a synthetic analog of **vasopressin** (ADH) that is modified to have much higher selectivity for **V2 receptors** in the renal collecting ducts, leading to potent **antidiuretic effects** [1], [3]. - This selective action results in significantly **reduced vasoconstrictor activity** (mediated by V1 receptors) compared to natural vasopressin, making it safer for clinical use to manage water balance without significant cardiovascular side effects [1], [3]. *Is more potent than vasopressin* - While desmopressin is indeed more potent in its **antidiuretic effect** due to increased affinity for **V2 receptors**, this option alone doesn't specify the critical advantage of *reduced vasoconstrictor activity* [3]. - Its superior potency alone doesn't fully explain its preference over vasopressin, as the **side-effect profile** is a major consideration. *Has little vasoconstrictor activity* - This statement is true and highlights a key advantage of desmopressin, but it omits the fact that **desmopressin is also more potent** in its desired antidiuretic effect compared to natural vasopressin [1]. - Both the **potency** and **reduced vasoconstrictor activity** contribute to its superior clinical profile [3]. *Is more selective for V2 receptors than vasopressin* - **Desmopressin's increased selectivity** for **V2 receptors** is the mechanistic basis for its preferred properties, leading to both greater antidiuretic potency and reduced vasoconstriction [1], [4]. - However, the option "Is more potent and has little vasoconstrictor activity" describes the *clinical consequences* of this selectivity, which are the direct reasons for its preferred use [2].
Question 60: Which of the following has the least glucocorticoid activity?
- A. Fludrocortisone
- B. Cortisone (Correct Answer)
- C. Dexamethasone
- D. Betamethasone
Explanation: ***Cortisone*** - **Cortisone has the LEAST glucocorticoid activity** among the options listed. - It is a **prodrug** that must be converted to **hydrocortisone (cortisol)** by 11β-hydroxysteroid dehydrogenase in the liver to become active. - Its glucocorticoid potency is approximately **0.8** relative to hydrocortisone (when hydrocortisone = 1). - Due to variable hepatic conversion, it has **lower and less predictable glucocorticoid effects** compared to other agents. *Fludrocortisone* - Primarily used for its **potent mineralocorticoid activity** (125× that of hydrocortisone). - However, it retains **significant glucocorticoid activity** approximately **10-15 times** that of hydrocortisone. - Despite being marketed as a mineralocorticoid, its glucocorticoid potency is **considerably higher than cortisone**. *Dexamethasone* - **Highly potent synthetic glucocorticoid** with negligible mineralocorticoid activity. - Glucocorticoid potency is approximately **25-30 times** that of hydrocortisone. - Long duration of action (36-72 hours) and excellent CNS penetration. *Betamethasone* - **Highly potent synthetic glucocorticoid**, structurally similar to dexamethasone (differs only in stereochemistry at C-16). - Glucocorticoid potency is approximately **25-30 times** that of hydrocortisone. - Minimal mineralocorticoid activity, with similar clinical applications to dexamethasone.